Related Experiment Video
Updated: Dec 30, 2025
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study
Veli Sunar1, Vakkas Korkmaz, Serkan Akin
1University of Health Sciences, Zekai Tahir Burak Women's Health Training and Research Hospital, Ankara, Turkey.
Purpose:
Uterine sarcoma accounts for 3-9% of uterine malignant tumors and has poor prognosis. Pazopanib is an oral multi-kinase inhibitor and the only tyrosine kinase inhibitor which has been approved for metastatic soft tissue sarcoma. In the present study we aimed to evaluate the efficacy of pazopanib in metastatic uterine sarcoma.
Methods:
The data of 28 metastatic uterine sarcoma patients receiving pazopanib therapy, who were followed in four oncology centers in Ankara, Turkey between May 2013 and June 2018, were retrospectively analyzed. Patients over 18 years, ECOG performance status ≤ 2, receiving at least one line of chemotherapy for metastatic disease, measurable disease at diagnosis, and histologically proven uterine high grade sarcoma were the inclusion criteria. Progression-free survival (PFS), overall survival (OS), and response rates to pazopanib were retrospectively evaluated.
Results:
The median age was 53 years (range, 26-76). The majority of the patients had uterine leiomyosarcoma (LMS) (n=25, 89.3%), 2 (7.1%) had undifferentiated uterine sarcoma (UUS), and 1(3.6%) had high grade endometrial stromal sarcoma (ESS). The most common site of metastasis was lung (n: 21, 75%). The median time for pazopanib therapy was 5 months (0.6-28.3). In 22 patients (78.5%), pazopanib was discontinued due to disease progression, while 2 patients (7.1%) quitted therapy owing to toxicity. Partial response was achieved in 4 patients (14.3%), while 17 (60.7%) had stable disease. Median PFS was 5.2 months (95% CI 2.8-7.5) and median OS was 11.4 months (95% CI 3.4-19.5).
Conclusion:
In the present study aiming to assess the real-life outcome of pazopanib-treated patients, we found that pazopanib is efficient in metastatic uterine sarcoma, and our results correspond to the literature.
Insights
Pazopanib shows efficacy in treating metastatic uterine sarcoma, offering a median progression-free survival of 5.2 months. This study evaluated pazopanib (a multi-kinase inhibitor) in patients with advanced uterine sarcoma.
Area of Science:
- Oncology
- Medical Science
- Pharmacology
Background:
- Uterine sarcoma is a rare gynecologic malignancy with a poor prognosis, accounting for 3-9% of uterine cancers.
- Pazopanib is an approved oral multi-kinase inhibitor for metastatic soft tissue sarcoma, but its efficacy in uterine sarcoma is less established.
Purpose of the Study:
- To evaluate the real-world efficacy of pazopanib in patients with metastatic uterine sarcoma.
- To assess progression-free survival (PFS), overall survival (OS), and response rates in this patient cohort.
Main Methods:
- Retrospective analysis of 28 metastatic uterine sarcoma patients treated with pazopanib across four centers in Turkey (May 2013 - June 2018).
- Inclusion criteria included age >18, ECOG performance status ≤2, prior chemotherapy for metastatic disease, measurable disease, and high-grade uterine sarcoma.
- Key outcomes evaluated were PFS, OS, and objective response rates.
Main Results:
- The majority of patients had uterine leiomyosarcoma (89.3%). The most common metastatic site was the lung (75%).
- Median PFS was 5.2 months and median OS was 11.4 months.
- Partial response was observed in 14.3% of patients, with stable disease in 60.7%. Disease progression led to discontinuation in 78.5% of patients.
Conclusions:
- Pazopanib demonstrates efficacy in metastatic uterine sarcoma, aligning with existing literature.
- The findings support the use of pazopanib as a treatment option for patients with advanced uterine sarcoma, warranting further investigation.
